Michael Mauro is Attending Physician, Professor of Medicine, Director, Chronic Myeloid Leukemia Program, and Member, Memorial Sloan Kettering Cancer Center, in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. His research interests are development of novel agents for CML, increasing the option of treatment free remission (TFR) / functional cure in CML and identification and management of tyrosine kinase inhibitor related adverse events, specifically cardiovascular events. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.